Published mark
CalciMedica, Inc.
NASDAQ: CALC. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca
- SEC CIK
- 0001534133
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- Apr 29, 2025
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- A. Rachel Leheny, Ph.D.Since Apr 29, 2025
- Chair
- Not published
- Independent
- 4 / 77 directors published
- Published claims
- 282 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
A. Rachel Leheny, Ph.D. executive of CalciMedica, Inc., effective 2025-04-29.
EffectiveEffective Apr 29, 2025E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Executive Officer and Class II Director | A. Rachel Leheny, Ph.D. | Apr 2025 | current | Source reportedE3 |
| Chief Business Officer and Class II Director | Eric W. Roberts | Apr 2025 | current | Source reportedE4 |
| Chief Scientific Officer | Kenneth A. Stauderman, Ph.D. | Apr 2025 | current | Source reportedE5 |
| President and Chief Operating Officer | Michael J. Dunn, MBA | Apr 2025 | current | Source reportedE6 |
| Chief Financial Officer | Stephen Bardin, MBA | Apr 2025 | current | Source reportedE7 |
| Chief Medical Officer | Sudarshan Hebbar, M.D. | Apr 2025 | current | Source reportedE8 |
Board of directors
Evidence7 directors published. 4 of 7 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| A. Rachel Leheny, Ph.D. | Not independent | 2023 | None published | Source reportedE2 |
| Alan Glicklich, M.D. | Independent | 2025 | None published | Source reportedE2 |
| Allan Shaw | Independent | 2023 | Audit, chairAudit · Chair; Compensation · Chair; Nominating and GovernanceCompensation, chairNominating and Governance | Source reportedE2 |
| Eric W. Roberts | Not independent | 2023 | None published | Source reportedE2 |
| Fred Middleton | Independent | 2023 | AuditAudit; CompensationCompensation | Source reportedE2 |
| Frederic Guerard, Pharm.D. | Not independent | 2023 | None published | Source reportedE2 |
| Ryan Wilson | Independent | 2023 | AuditAudit; Compensation; Nominating and Governance · ChairCompensationNominating and Governance, chair | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Allan Shaw | Allan Shaw, Fred Middleton, Ryan Wilson | Not described in the published record |
| Audit · Chair; Compensation · Chair; Nominating and Governance | Not published | Allan Shaw | Not described in the published record |
| Audit; Compensation | Not published | Fred Middleton | Not described in the published record |
| Audit; Compensation; Nominating and Governance · Chair | Not published | Ryan Wilson | Not described in the published record |
| Compensation | Allan Shaw | Allan Shaw, Fred Middleton, Ryan Wilson | Not described in the published record |
| Nominating and Governance | Ryan Wilson | Ryan Wilson, Allan Shaw | Not described in the published record |
Committee RecordAudit: Chair Allan Shaw; Members Allan Shaw (Chair); Fred Middleton; Ryan Wilson
Committee AppointmentAllan Shaw: chair, Audit
Committee AppointmentFred Middleton: member, Audit
Committee AppointmentRyan Wilson: member, Audit
Committee RecordCompensation: Chair Allan Shaw; Members Allan Shaw (Chair); Fred Middleton; Ryan Wilson
Committee AppointmentAllan Shaw: chair, Compensation
Committee AppointmentFred Middleton: member, Compensation
Committee AppointmentRyan Wilson: member, Compensation
Committee RecordNominating and Governance: Chair Ryan Wilson; Members Ryan Wilson (Chair); Allan Shaw
Committee AppointmentRyan Wilson: chair, Nominating and Governance
Committee AppointmentAllan Shaw: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerA. Rachel Leheny, Ph.D., Chief Executive Officer and Class II Director, from Apr 29, 2025
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingCALC (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 15, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameCalciMedica, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- A. Rachel Leheny, Ph.D.Chief Executive Officer and Class II Directorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:12, company:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:5
- Eric W. RobertsChief Business Officer and Class II Directorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:13, company:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:8
- Kenneth A. Stauderman, Ph.D.Chief Scientific Officercompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:14
- Michael J. Dunn, MBAPresident and Chief Operating Officercompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:15
- Stephen Bardin, MBAChief Financial Officercompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:16
- Sudarshan Hebbar, M.D.Chief Medical Officercompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:17
- Alan Glicklich, M.D.Directorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:6
- Allan ShawDirectorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:7
- Fred MiddletonDirectorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:9
- Frederic Guerard, Pharm.D.Directorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:10
- Ryan WilsonDirectorcompany:2087a65e-d9c3-4fd8-8f5d-0ac1ae56aaca:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 29, 2025. Retrieved Apr 28, 2026. Cited by 7 Claims.
- E3sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 29, 2025. Retrieved May 16, 2026. Cited by 1 Claim.
- E9board_seats. board seats. Cited by 11 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- A. Rachel Leheny, Ph.D. executive of CalciMedica, Inc., effective 2025-04-29.
- Eric W. Roberts executive of CalciMedica, Inc., effective 2025-04-29.
- Kenneth A. Stauderman, Ph.D. executive of CalciMedica, Inc., effective 2025-04-29.
- Michael J. Dunn, MBA executive of CalciMedica, Inc., effective 2025-04-29.
- Stephen Bardin, MBA executive of CalciMedica, Inc., effective 2025-04-29.
- Sudarshan Hebbar, M.D. executive of CalciMedica, Inc., effective 2025-04-29.
- Alan Glicklich, M.D. seat on CalciMedica, Inc., effective 2025-01-01.
- A. Rachel Leheny, Ph.D. seat on CalciMedica, Inc., effective 2023-01-01.
- Allan Shaw seat on CalciMedica, Inc., effective 2023-01-01.
- Eric W. Roberts seat on CalciMedica, Inc., effective 2023-01-01.
- Fred Middleton seat on CalciMedica, Inc., effective 2023-01-01.
- Frederic Guerard, Pharm.D. seat on CalciMedica, Inc., effective 2023-01-01.
- Ryan Wilson seat on CalciMedica, Inc., effective 2023-01-01.
- Audit · Chair; Compensation · Chair; Nominating and Governance committee of CalciMedica, Inc., effective 2023-01-01.
- Allan Shaw member of Audit · Chair; Compensation · Chair; Nominating and Governance, effective 2023-01-01.
- Audit; Compensation committee of CalciMedica, Inc., effective 2023-01-01.
- Fred Middleton member of Audit; Compensation, effective 2023-01-01.
- Audit; Compensation; Nominating and Governance · Chair committee of CalciMedica, Inc., effective 2023-01-01.
- Ryan Wilson member of Audit; Compensation; Nominating and Governance · Chair, effective 2023-01-01.